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• Previous analytical studies have shown that GP2017 and reference adalimumab have identical amino acid sequences, indistinguishable secondary and tertiary structures, the same level of post-translational modifications and similar in vitro functionality.
What does this study add?
• This phase III confirmatory efficacy and safety study demonstrated equivalent efficacy and similar safety of GP2017 and reference adalimumab in patients with moderate-to-severe plaque psoriasis.
• Additionally, switching up to four times between GP2017 and reference adalimumab had no impact on the incidence of adverse events or injection-site reactions.
• The frequency of antidrug antibody development was similar between the switched and continued treatment groups, and there was no impact on efficacy.
A biosimilar medicine can only be authorized if it has the same safety and efficacy profile as the reference medicine, and clinically relevant changes in treatment are not expected upon switching from the reference medicine to a biosimilar medicine (or vice versa). 1 Although prescribing biosimilars to biologicnaive patients is well accepted, switching patients between reference and biosimilar medicines may be a concern for clinicians due to lack of clinical data and recommendations. 2, 3 Concerns surrounding switching to biosimilars include the possibility of increased immunogenicity, safety issues and even loss of efficacy. 4 All biologics have the potential to trigger an immune response, which primarily manifests as the production of antidrug antibodies (ADAs). This can lead to altered pharmacokinetics, reduced clinical efficacy and an increased risk of adverse events (AEs). 5 As authority-approved biosimilars and their reference medicines contain essentially the same active substance, it is reasonable to assume that there will be no difference in how a patient's immune system reacts to the two medicines upon switching. 6 Nevertheless, the risk of enhanced hypersensitivity or anaphylactic reactions remains a key concern among physicians. 2, 3 Adalimumab is indicated for use in rheumatoid arthritis, psoriatic arthritis (PsA), plaque psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, Crohn disease, ulcerative colitis and uveitis. 7, 8 GP2017 is being developed by Sandoz, a Novartis Division, as a proposed biosimilar to adalimumab. Here, results from a phase III confirmatory efficacy and safety study comparing GP2017 with reference adalimumab (ref-ADMB) in patients with plaque psoriasis are reported. Notably, four switches between ref-ADMB and GP2017 were included in the study design to evaluate the impact of multiple switches on efficacy, safety and immunogenicity.
Patients and methods

Study conduct
The study, sponsored by Hexal AG, a Sandoz company, was conducted in accordance with the ethical principles of the Declaration of Helsinki and approved by the independent ethics committee or institutional review board for each study centre. An independent data monitoring committee was responsible for monitoring safety and study conduct. All patients provided written informed consent before entering the study. A principal investigator list is provided in Appendix S1 (see Supporting Information). The study is registered at ClinicalTrials.gov, identifier NCT02016105.
Study design and treatment
This was a randomized, multicentre phase III confirmatory study consisting of four periods: screening, treatment period 1 (TP1, randomization to week 17), treatment period 2 (TP2, weeks 17-35) and an extension period (weeks 35-51) (Fig. 1) . The study was double blinded; patients, investigator staff and the people performing the study assessments remained blinded to the identity of the given treatments until week 51. Prior to randomization, a 6-month washout period was required for tumour necrosis factor antagonists or biologic immunomodulating agents, or a 4-week washout period for other systemic immunomodulating or psoriasis treatments. During the study, patients were prohibited from receiving any nonstudy treatments for psoriasis. Treatments for PsA were permitted if given at a stable dose for ≥ 4 weeks prior to study entry.
In TP1, eligible patients were 
Study objectives and assessments
The primary objective of the study was to demonstrate equivalent efficacy for GP2017 and ref-ADMB in terms of the proportion of patients who achieved PASI 75 at week 16. The key secondary objective was to compare the percentage change from baseline in continuous PASI up to week 16. Other objectives in TP1 and the following study periods included comparisons of PASI 50, 75, 90 and 100 response rates, PASI over time, IGA of disease activity, pharmacokinetics, safety, tolerability and immunogenicity for the switched and continued treatment groups. Visits were scheduled every 2 weeks during TP1, and every 6 weeks thereafter. At each visit, efficacy, safety and tolerability were assessed. The occurrence and severity of AEs and injection-site reactions (ISRs; defined as the occurrence of pruritus, haematoma, erythema, bruising, swelling, urticaria, induration or pain at the site of administration) were recorded at all visits. A validated, multitiered electrochemiluminescence bridging immunogenicity assay was used to determine ADA titres, and a competitive ligand binding assay was used to assess the neutralizing capacity of ADAs. Trough serum drug concentrations were collected at the same time points as immunogenicity samples and were analysed using a validated enzyme-linked immunosorbent assay.
Statistical analyses
The sample size was calculated based on PASI 75 response rates reported in prior clinical trials with ref-ADMB. size of 448 patients (to maintain 380 evaluable patients) was required to provide a power of 90% to show equivalence between treatments. The study was powered for the primary and key secondary objectives (Appendix S1; see Supporting Information); all other results, including those associated with multiple switching, are descriptive in nature only.
In line with guidance from the U.S. Food and Drug Administration (FDA), efficacy analyses were conducted using the per protocol analysis set. The per protocol set is considered conservative, as protocol violators who could bias study results towards equivalence are excluded. 11 Supportive analyses were performed using the full analysis set. Safety data were analysed using the safety analysis set (Table S1 ; see Supporting Information).
Results
Patients and treatment
Between December 2013 and March 2015, 465 patients were randomized and treated at 73 study centres in Bulgaria, France, Slovakia and the U.S.A. During TP1, 231 and 234 patients were randomized to GP2017 and ref-ADMB, respectively ( Fig. S1 ; see Supporting Information). In TP2, 379 (81Á5%) patients were rerandomized: 126 patients to undergo treatment switching (between ref-ADMB and GP2017) and 253 patients to continue their original treatment. The study was completed by 301 (64Á7%) patients, with the main reason for discontinuation being patient decision (≤ 6Á5% of patients). The incidence of discontinuations due to AEs was ≤ 3Á8% per treatment group. The mean age at baseline was 46Á3 years, and approximately two-thirds of patients (61Á1%) were male. Most patients (85Á4%) were white. Patients had a mean body weight of 91Á9 kg and a mean body mass index of 31Á1 kg m À2 . The mean duration of plaque psoriasis was 16Á1 years, and 21Á1% of patients had PsA. At randomization, the mean PASI was 20Á1, and all patients had an IGA score of 3 (moderate, 65Á8%) or 4 (severe, 34Á2%). Most patients (87Á5%) had received prior psoriasis therapy, most commonly topical treatment (76Á3%), with 21Á1% of patients having received prior biologic systemic therapy. There were no clinically relevant differences in baseline demographics or disease characteristics between patients randomized to GP2017 or ref-ADMB in TP1, or rerandomized into the switched or continued treatment groups in TP2 (Table S2 ; see Supporting Information). Exposure to the study drug was similar during TP1, and between the switched and continued treatment groups from week 17 to week 51 (Table S3 ; see Supporting Information). Due to the 2 : 1 ratio at rerandomization, patient exposure in years was approximately twice as high in the continued treatment groups as in the switched treatment groups.
Efficacy
Primary and key secondary objectives
The primary and key secondary objectives of the study were met ( Table 1) . As the 95% confidence intervals were contained within the prespecified margins, equivalent efficacy between GP2017 and ref-ADMB was confirmed in both the per protocol set and full analysis set. No significant differences were observed in subgroups of patients who had or had not received prior systemic therapy (Table S4 ; see Supporting Information). 
Psoriasis Area and Severity Index over time
During TP1, mean absolute PASI and mean percentage changes from baseline improved over time and were similar between the GP2017 and ref-ADMB treatment groups. For patients rerandomized after TP1, the mean absolute PASI and mean percentage changes from baseline remained similar in the switched and continued treatment groups during weeks 17-51 (Fig. 2) . Similar results were seen for PASI 50, 75, 90 and 100 response rates (data not shown).
Pharmacokinetics
Mean trough serum drug concentrations were stable from week 3 (first postdose assessment) over the 51-week period for all treatment groups, remaining within the ranges given in the reference medicine label (approximately 5000-10 000 ng mL À1 ). 7, 8 The means and variability for GP2017 and ref-ADMB were similar at all time points up to week 17, and for the switched and continued treatment groups for weeks 17-51 ( Fig. S2 ; see Supporting Information).
Safety
During TP1, 239 patients (51Á4%) reported a total of 541 AEs. There were no relevant differences with respect to proportions reporting AEs (overall and treatment related), serious AEs, severe AEs, AEs of special interest, AEs requiring study drug interruption or discontinuations due to AEs (Table 2) . Infections and infestations were the most commonly affected system organ class (23Á9%), with nasopharyngitis most frequently reported (6Á0%) ( Table S5 ; see Supporting Information). Except for basal cell carcinoma, preferred terms for AEs of special interest were reported by no more than two patients in either treatment group (Table S6 ; see Supporting Information). There were no relevant differences between the switched and continued treatment groups with respect to the proportions reporting AEs and serious AEs during weeks 17-51 ( Table 2) . Rates of reported AEs were similar for most system organ classes and preferred terms. Differences of > 10% were seen in gastrointestinal disorders, which were reported by 3Á2% of patients in the ref-ADMB to GP2017 group compared with 14Á2% of patients in the continued ref-ADMB group. Preferred terms were generally reported by < 5% of patients in any treatment group, except for nasopharyngitis, upper respiratory tract infection, hypertension and headache (Table S7; see Supporting Information). One patient in the continued GP2017 group (with a history of depression) died on day 178 (TP2) due to suicide; this was not considered to be related to study treatment.
Differences in the proportions of patients with AEs of special interest were < 5% across the switched or continued treatment groups ( Table 2) . No clustering of any AE of special interest was observed; except for thrombocytopenia, herpes zoster and anaemia, events of each preferred term were reported for no more than one patient per group (Table S6) . No hypersensitivity to adalimumab was reported upon switching.
Tolerability
During TP1, the proportion of patients reporting ISRs was 6Á5% with GP2017 and 3Á4% with ref-ADMB. During weeks 17-51, the proportion of patients reporting ISRs remained at < 4Á8% per treatment group and was similar across the switched and continued treatment groups (Table 2 ). Most ISRs were of mild or moderate severity; one patient who switched from GP2017 to ref-ADMB reported severe injection-site pain. None of the ISRs reported during the study were considered serious, and no allergic or anaphylactic reactions were reported.
Immunogenicity
During TP1, the proportions of patients reporting at least one positive ADA response up to week 17 were 36Á8% and 34Á1% in the GP2017 and ref-ADMB groups, respectively. Of these, 80% in each group were neutralizing antibodies ( Table 3) . The proportions of patients with at least one positive ADA response were similar in the ref-ADMB to GP2017 group (39%) and the continued GP2017 group (35Á8%). The rate was 45Á1% in the continued ref-ADMB group and 47% in the group that switched from GP2017 to ref-ADMB. In the switched and continued treatment groups, most ADA-positive patients (75-100%) also tested positive for neutralizing antibodies. The proportions of patients developing ADAs after the first treatment switch were similar.
Discussion
Equivalent efficacy between GP2017 and ref-ADMB was confirmed in this phase III study in patients with moderate-to-severe chronic plaque psoriasis. Together with evidence of comparable safety and immunogenicity up to week 17, the data contribute to 
Values are n (%). AE, adverse event; EP, extension phase; ref-ADMB, reference adalimumab; SAE, serious AE; TP, treatment period. a Ten patients had an SAE that was considered treatment related, comprising severe toxic skin eruption, moderate pneumonia, severe cellulitis (TP1, ref-ADMB); severe staphylococcal infection and severe hypersensitivity (both in one patient; TP1, GP2017), severe pneumonia and moderate pyrexia (TP2 + EP, ref-ADMB to GP2017 group), severe pulmonary tuberculosis, severe necrotizing pneumonia and moderate pneumonia (TP2 + EP, continued ref-ADMB group) and moderate pyelonephritis (TP2 + EP, continued GP2017 group).
b Encompasses all the warnings and precautions given in the label for ref-ADMB, including infections, malignancy, allergic or anaphylactic reactions, immune system disorders or autoimmune events, neurological events, haematological events, congestive heart failure and interstitial lung disease. the totality of evidence established from previous analytical, preclinical and pharmacokinetic studies, [12] [13] [14] and are considered supportive for claiming biosimilarity between GP2017 and ref-ADMB. To our knowledge, clinical studies assessing the efficacy and safety of adalimumab biosimilars performed so far either have not assessed multiple switches or, at best, have included one single switch from the reference medicine to the biosimilar. 15, 16 As biological medicines are typically large, complex glycoprotein molecules produced in living organisms, it is impossible to produce an identical copy. As a result, inherent batch-to-batch variability exists for all biologics, even between different batches of the same reference medicine. 17 It is important for clinicians to understand that, to a certain extent, repeated switching already occurs when different batches of the reference medicine are prescribed to a given patient. However, while clinical data showing the impact of batch-to-batch variability are limited, 18 clinical studies of biosimilars have provided extensive data demonstrating that minor and nonclinically relevant variations between two molecules, which were designed to be highly similar, do not have a detrimental effect on clinical safety and efficacy. 19 Consequently, two products with (i) identical amino acid sequence, highly similar physicochemical, structural and in vitro functional properties and (ii) comparable pharmacokinetics, safety and efficacy are not expected to elicit different clinical effects in individual patients upon treatment switching. 6 Nonetheless, concerns have been raised that switching from reference medicines to biosimilars may lead to increased immunogenicity and consequential safety problems, or even a loss of efficacy. 2, 4 Furthermore, in the setting of chronic conditions, such as immune-mediated inflammatory disorders, patients are often scheduled to receive the same biological medicine for years. With the presence of several biosimilars of the same reference medicine on the market, it is conceivable that patients are now more likely to switch several times between different biosimilars. Concerns have been raised regarding differences in the incidence or type of AEs, as well as the potential for increased immunogenicity leading to hypersensitivity reactions and/or decreased effectiveness. 2, 3 This may be of particular concern for adalimumab, which has higher intrinsic immunogenicity than other anti-tumour necrosis factor molecules. [20] [21] [22] Generation of data, either in real-world situations or in clinical trials assessing the impact of multiple switches between a reference medicine and biosimilar, would be beneficial to address these concerns. These data will reassure clinicians when prescribing biosimilars, and help to address fears that multiple switching between reference medicines and their biosimilars may have negative consequences. 2, 3 In addition to the required regulatory assessment of biosimilarity, the present study was designed to investigate the impact of multiple switches between ref-ADMB and GP2017, a proposed biosimilar to adalimumab. To our knowledge, the study represents the most treatment switches investigated to date. Importantly, switching between ref-ADMB and GP2017 up to four times in a subset of patients had no detectable impact on efficacy, safety or immunogenicity. There were no new or unexpected safety issues arising during treatment switching, and the proportion of patients with AEs was similar across both the switched and continued treatment groups for most system organ classes and preferred terms. Furthermore, the incidences of AEs and ISRs did not increase with multiple treatment switches. The frequency of ADA development was similar across switched and continued treatment groups, and there was no detectable impact on efficacy, as PASI and percentage change from baseline in PASI remained similar across the switched and continued treatment groups over time.
The results support emerging data on switching, from clinical trials and registries in many indications. 2, 3, 16, [23] [24] [25] [26] For example, in the recent NOR-SWITCH study, single switches from reference to biosimilar infliximab in patients with Crohn disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, PsA and psoriasis were not inferior to continued treatment with the reference medicine, and safety and immunogenicity were similar between patients who switched or continued treatment. 23 The present study and analysis of switching data have some limitations. Most importantly, as the primary focus of the study was to assess biosimilarity, it was not powered to assess treatment switching. Many of the concerns regarding treatment switching relate to switching patients on stable treatment with the reference medicine to a biosimilar; therefore, a longer leadin period of treatment with ref-ADMB may have been preferred. However, patients receiving long-term treatment are less likely to develop ADAs, 27 and thus represent a less immunocompetent (sensitive) population for assessing immunogenicity, particularly in the setting of multiple switches. In the coming years, clinicians will likely have access to multiple biosimilars of the same reference medicine. Studies that examine the effects of multiple switches from reference biologics to different biosimilars within the same product class will be important to clinical practice. Guidance on interchangeability issued by the FDA will also need to be considered in future trial designs. 28 Although specific regulatory
requirements are yet to be finalized, the FDA is the only regulatory agency with a statutory definition of interchangeability. For such a designation to be granted, the FDA recommends that specific studies are performed to assess the impact of switching on clinical pharmacokinetics and pharmacodynamics, as it believes these parameters are more likely to be sensitive to changes in immunogenicity and/or exposure than measures of efficacy. 28 The requirements to demonstrate interchangeability between a biosimilar and a reference medicine are more extensive than those outlined in the FDA guidance on chemistry, manufacturing and controls, for postapproval manufacturing changes for specified biological products. 28, 29 In the European Union, the decision to switch between an approved biosimilar and its reference medicine is regulated on a national level.
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Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's website: Appendix S1 List of investigators, inclusion and exclusion criteria and statistical analyses. Table S4 Primary and key secondary efficacy results in the subgroups of patients who had or had not received systemic therapy prior to study treatment. Table S5 Adverse events regardless of study treatment relationship by system organ class and preferred term in treatment period 1. Table S6 Overall incidence of adverse events of special interest by treatment group (safety analysis set). Table S7 Adverse events regardless of study treatment relationship by system organ class and preferred term in treatment period 2 + extension period (safety analysis set).
